IMR Press / FBL / Volume 16 / Issue 6 / DOI: 10.2741/3850

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Dramatic improvement of DC-based immunotherapy against various malignancies
Show Less
1 R and D Laboratory for Innovative Biotherapeutics, Kyushu University Graduate School of Pharmaceutical Sciences, Fukuoka 812-8582, Japan
2 Departments of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan

Academic Editor: Mukesh Agarwal

Front. Biosci. (Landmark Ed) 2011, 16(6), 2233–2242;
Published: 1 June 2011
(This article belongs to the Special Issue Novel strategies for detection, prevention and treatment of cancer)

Dendritic cells (DCs) play a crucial role in maintaining the immune system. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, clinical efficacies are still insufficient in many human trials. To identify the causes of the low efficacies, we paid attention to their numbers and how they are activated. We proved that DCs' antitumor effect depends on their number and the way they are activated. We here established a possible breakthrough, a simple cytokine-based culture method to realize a log-scale order of functional murine/human DCs. Moreover, we demonstrated that DCs activated by replication-deficient recombinant Sendai virus (rSeV) were dramatically more effective than that seen in the use of current DC vaccine for immunotherapy against malignancies. Our study could overcome these problems and would improve treatment of malignancies.

Back to top